Why would GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), one of the world’s largest pharmaceutical companies, want to get out of the business of treating cancer? Following its deal with Novartis, that’s exactly what it has done… in this video, Owain Bennallack explains why he thinks it is a strong move.
(Video) GlaxoSmithKline plc Gives Up On Cancer
One Fool puts GlaxoSmithKline plc (LON:GSK) under the spotlight.
The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.